4-acetylmorpholine

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

supporting study

Study period:

1967-03-22 to 1967-04-05

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Study predating guidelines and GLP, but according to data owner, performed close to OECD TG 401.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1967

Report date:

1967

Materials and methods

Test guideline

Qualifier:

no guideline followed

Guideline:

other:

Deviations:

not applicable

Principles of method if other than guideline:

BASF test (single i.p. administration of test item to mice)

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

4-acetylmorpholine

EC Number:

216-913-4

EC Name:

4-acetylmorpholine

Cas Number:

1696-20-4

Molecular formula:

C6H11NO2

IUPAC Name:

1-(morpholin-4-yl)ethan-1-one

Details on test material:

- Name of test material: N-Acetylmorpholin

Test animals

Species:

mouse

Strain:

other: "Kisslegg"

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: 25 - 34 g (males); 14 - 28 g (females)

ENVIRONMENTAL CONDITIONS
- no data

IN-LIFE DATES: From: 22.03.1967 To: 05.04.1967

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

other: aqueous traganth emulsion

Details on exposure:

VEHICLE
- Vehicle concentration: 30% (6400, 5000, 4000, 3200, 2500 mm3/kg bw) , 20% (1600 mm3/kg bw), 2% (200 mm3/kg bw)

MAXIMUM DOSE VOLUME APPLIED:
21, 3 mL / kg

Doses:

6400, 5000, 4000, 3200, 2500, 1600 or 200 mm3/kg bw, corresponds to:
7136, 5575, 4460, 3568, 2788, 1784 or 223 mg / kg bw; calculation based on density of test item

No. of animals per sex per dose:

5 males and 5 females

Control animals:

no

Details on study design:

- Duration of observation period following administration: 7 days
- Frequency of observations and weighing: body weight taken at study start only for dose determination, but not reported
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs monitored but frequency unknown, gross necropsy on fatalities

Statistics:

not performed

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

ca. 3 000 mg/kg bw

Mortality:

6400 mm3 / kg bw: 9/10 (9/10 within 24 h, 1 male survived 7 days)
5000 mm3 / kg bw: 10/10 (9/10 within 24 h, 10/10 within 48 h)
4000 mm3 / kg bw: 8/10 (3/10 within 24 h, 8/10 within 48 h, 1 male / 1 female survived 7 days)
3200 mm3 / kg bw: 6/10 (0/10 within 24 h, 4/10 within 48 h - 1 male/3 females died, 6/10 within 7 days - 2 females died, 4 males survived 7 days)
2500 mm3 / kg bw: 0/10
1600 mm3 / kg bw: 0/10
1600 mm3 / kg bw: 0/10

Clinical signs:

6400 - 4000 mm3 / kg bw: saltatory convulsions immediately after injection, vocalisations indicating pain, laboured breathing, ruffled fur, licking of injection site; after 15 min at 6400 mm3 / kg bw: prone/lateral position with streched legs; animals surviving the first 24 hours were found in prone/lateral position, mild twitching, tremor, dyspnoe and clotted eyes. Within next two days: motor activity mildly decreased, then recuperating.
3200 and 2500 mm3 / kg bw: same symptoms as above, but milder
1600 and 200 mm3 / kg bw: on the day of application laboured breathing, prone position, ruffled fur, ptosis. Animals recuperated until day 2.

Body weight:

No data reported

Gross pathology:

perished animals: yellowish-pallid liver due to fatty degeneration (4x), intestinal atony (4x), blotched pallid livers, kidneys pallid, increased intraperitoneal liquids, smell of test item
Killed animals: no findings for organs, (yellowish-pallid liver, fatty degeneration questionable (2x), clottings (2x), adhesions (1x))